

**VIVALIS ANNOUNCES A NEW EB66<sup>®</sup> CELL LINE COMMERCIAL LICENSE AGREEMENT WITH FARVET FARMACOLÓGICOS VETERINARIOS**

**Nantes & Lyon (France) – 20 June 2012** – VIVALIS (NYSE Euronext: VLS) announced today that it has signed a non-exclusive commercial license agreement for up to three products with Farvet Farmacológicos Veterinarios SAC (“FARVET”) for the development and marketing of animal health vaccines produced in the EB66<sup>®</sup> cell line.

Under this agreement VIVALIS will transfer the EB66<sup>®</sup> cell line and know-how to FARVET for the commercial development of poultry-based veterinary vaccines. FARVET will have the rights to commercialize one vaccine product with an option to develop two additional products under the same agreement in selected countries in South and Central America. Upfront and milestone payments along with royalties on net-sales to Vivalis apply to all three candidates.

Dr. Manolo Fernandez Díaz, General Manager of FARVET declared, “This is a major step forward in the growth and future of FARVET, with it being the first company in South America to use VIVALIS’ EB66<sup>®</sup> platform. The benefits of the EB66<sup>®</sup> cell technology for veterinary vaccines demonstrate a unique and revolutionary alternative for the effective antigenic manufacturing of vaccines currently produced in SPF eggs. The high efficiency of the EB66<sup>®</sup> cell technology makes it attractive system and we are very pleased to work with VIVALIS and hope to grow with them in the future.”

Franck Grimaud, CEO, and Majid Mehtali, CSO, co-managers of VIVALIS jointly stated, “Our expansion of the EB66<sup>®</sup> platform into the South American market has been met with initial success. The benefits of our EB66<sup>®</sup> technology, in particular for veterinary products, allows the efficient production of animal health vaccines in a large scale, cell-based manufacturing platform. In situations where manufacturing in traditional systems such as chicken eggs is not optimal or desired, EB66<sup>®</sup> cells offer an economical alternative for the production of these products. We look forward to further developing our relationship with FARVET as they continue to grow in these highly opportunistic markets.”

Financial terms of the agreement were not disclosed.

\*\*\*\*\*

**Next Financial Press Release**

**July 19, 2012, after NYSE Euronext market closing: Second Quarter 2012 Revenues**

## **About Farvet Farmacológicos Veterinarios ([www.farvet.com](http://www.farvet.com))**

Today, FARVET is ready to meet the challenge of maintaining a leading position in the national and international veterinary pharmaceutical market, developing and innovating high quality products and molecular biology tools for the poultry industry, all guided by a quality management system for all its processes.

FARVET, is a pharmaceutical company engaged in the manufacture of pharmaceutical and biological products for the poultry industry in Peru. FARVET began operations in March 1983 and was the first Peruvian veterinary laboratory to produce vaccines against inclusion body hepatitis virus and avian laryngotracheitis. With main activities being the manufacturing, marketing, and distribution of biological products for the poultry industry, FARVET continues to grow in existing and future markets.

## **About VIVALIS ([www.vivalis.com](http://www.vivalis.com))**

VIVALIS (NYSE Euronext: VLS) is a biopharmaceutical company that provides innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and proteins, and develops drugs for the prevention and treatment of unmet medical needs. VIVALIS' expertise and intellectual property are leveraged in two main areas:

### EB66<sup>®</sup> Cell Line

VIVALIS offers research and commercial licenses for its EB66<sup>®</sup> cell line, derived from duck embryonic stem cells, to pharmaceutical and biotechnology companies for the production of therapeutic and prophylactic viral vaccines, virosomes, VLP's, and recombinant proteins (with a focus on monoclonal antibodies having enhanced cytotoxic activity). EB66<sup>®</sup> cell line based vaccines are currently in clinical trials in the USA and Japan. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

### VIVAIScreen<sup>™</sup> Human Antibody Discovery Platform

Customized solutions for the discovery, development, and production of fully human monoclonal antibodies are now offered by VIVALIS. Through these programs VIVALIS receives upfront, clinical stage milestone payments along with royalties on licensees net sales.

Based in Nantes & Lyon (France) and in Toyama (Japan) VIVALIS was founded in 1999 by the Grimaud Group (ca. 1,600 employees), a worldwide leader in animal genetic selection. VIVALIS has established more than 30 partnerships and licenses with world leaders in this sector, including Sanofi Pasteur, GlaxoSmithKline, Transgene, Pfizer Animal Health, Kaketsuken, Kitasato Daiichi Sankyo Vaccine, Merial, Merck Animal Health, and SAFC Biosciences. VIVALIS is a member of the French ATLANTIC BIOTHERAPIES and LYON BIOPOLE bioclusters and a member of the Japanese HOKURIKU INNOVATION CLUSTER FOR HEALTH SCIENCE in Toyama.

### **VIVALIS**

Listed on Euronext Paris – Compartment C of NYSE Euronext

Reuters: VLS.PA – Bloomberg: VLS FP

Included in NYSE Euronext's SBF 250, CAC Small 90 and Next Biotech indices



*This document contains forward-looking statements and comments on the company's objectives and strategies. No guarantee can be given to any of the events anticipated by the forward-looking statements contained in this document, which are subject to inherent risks, including risk factors described in the company's document de référence, changes in economic conditions, the financial markets or the markets in which the company operates.*

## **Contacts**

### **VIVALIS**

Franck Grimaud, CEO

Email: [investors@vivalis.com](mailto:investors@vivalis.com)

### **NewCap**

Financial communications agency

Pierre Laurent

Tel.: +33 (0) 1 44 71 94 91

Email: [vivalis@newcap.fr](mailto:vivalis@newcap.fr)